• The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months.
• Applications to join the Lab Hotel are welcome from start-ups working in advanced therapeutics and drug discovery.
• Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.
Stevenage Bioscience Catalyst (SBC) is offering free lab and office accommodation for start-ups – and space is available now. In addition to free accommodation, Lab Hotel occupiers receive scientific and business support,…
Coventry, United Kingdom, 10th March 2022 / NanoSyrinx, a biotech company using synthetic biology approaches to develop a new modality for the targeted intracellular delivery of biologic therapeutics, has strengthened its management team with the appointment of Dr Marie McAvoy as its Chief Scientific Officer.
Dr McAvoy joins NanoSyrinx from GSK where she was Senior Director in the Oncology Cell Therapy Research Unit. She brings more than 20 years of drug discovery experience in biotech and large pharma companies, having worked on vaccines, biopharmaceuticals and cell and gene therapies, and…
Huge demand for commercial lab and office space at Newcastle’s Biosphere means private sector investment is now being sought to take the lead on expanding the heart of the north east’s £1.7bn life science eco-system.
Located at Newcastle Helix, The Biosphere launched in 2019 as a publicly funded project, led by Newcastle City Council; it represented a significant investment for the local economy and showed a clear commitment to life sciences growth.
Potential investors from across the world will have the opportunity to find out more when Invest Newcastle (part of NewcastleGateshead…
Cambridge, UK, 7th March 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.
The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies with ambitious science and the ability to tackle major medical challenges, and Tencent, a global technology company investing in innovations that help improve human life. New…
Cambridge, United Kingdom, 3rd March 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, announces that it has purchased over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The new equipment will allow Domainex to increase its capacity and throughput, supporting its ongoing growth.
Included in the new equipment are two ACQUITY UPLC systems (one with an evaporative light scattering detector (ELSD) and one with…
https://blogs.deloitte.co.uk/health/2022/02/how-genomics-is-transformin…
In September 2021, to mark the first anniversary of the Deloitte Life Sciences Catalyst, we were privileged to attend an insightful hybrid webinar on The Future of Genomics.1 The webinar, chaired by Deloitte partner Mike Standing, was introduced by Frances Cousins who leads the Catalyst, and featured the following esteemed panellists: Professor Dame Sue Hill (Chief Scientific Officer for England), Dr David Bentley (Chief Scientific Officer of Illumina), Dr David Atkins (Chief Executive Officer of Congenica), Dr Julia…
Stevenage Bioscience Catalyst (SBC) has launched an accelerator programme to give start-ups working on data-enabled drug discovery, genomics and advanced therapies the skills they need to get potential new drugs and therapies to market more quickly.
The programme, which is offered at no cost, runs from May and is aimed at supporting start-up companies working to discover new drugs and therapies. Those selected will take part in an 18-week programme giving them the opportunity to network and learn from experts in the pharmaceutical and biotech industries. Start-ups will be able to build their…
Cambridge, UK, 01 March 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board. Dr Torbett joined PhoreMost as Chief Business Officer in January 2017 and was promoted to Chief Operating Officer in 2020, holding responsibility for all operational, scientific and commercial activities. During…
AMSBIO reports how researchers at the Washington University School of Medicine (St. Louis, USA) have used their 10E4 Heparan Sulfate (HS) antibody in pioneering obesity research to quantify the role of HS in the process of intercellular mitochondria transfer to macrophages.
In recent published research**, researchers from the Brestoff and Teitelbaum Labs demonstrated that adipose-tissue resident macrophages acquire mitochondria from adjacent adipocytes using HS. This process occurs in healthy conditions but is impaired in obesity. Further they have shown that genetic disruption of…